β2 Adrenoceptor Agonist Formoterol Stimulates Mitochondrial Biogenesis

Lauren P. Wills, Richard E. Trager, Gyda C. Beeson, Christopher C. Lindsey, Yuri K. Peterson, Craig C. Beeson and Rick G. Schnellmann


Ralph H. Johnson VA Medical Center Charleston, SC 29401: R.G.S.
Running Title: Formoterol Stimulates Mitochondrial Biogenesis

Corresponding Author:
Rick G. Schnellmann, PhD
Department of Pharmaceutical and Biomedical Sciences
Medical University of South Carolina
280 Calhoun St., MSC140
Charleston, SC 29425
Ph: 843-792-3754
Fax: 843-792-2620
Email: schnell@musc.edu

Number of Tables: 3
Number of Figures: 6
Number of References: 42
Number of Words in Abstract: 236
Number of Words in Introduction: 767
Number of Words in Discussion: 994

Abbreviations Used: AFC, adult feline cardiomyocytes; ATP6, ATP synthase F0 subunit 6 of transmembrane F-type ATP synthase; β-AR, β-adrenoceptor; DOI, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride; FCCP, carbonylcyanide p-trifluoromethoxyphenylhydrazone; i.p., intraperitoneal injection; LOPAC, Library of Pharmacologically Active Compounds; MB, mitochondrial biogenesis; mtDNA, mitochondrial DNA; ND1, NADH dehydrogenase subunit 1; ND6, NADH dehydrogenase subunit 6; NDUFB8, NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8;
OCR, oxygen consumption rate; PGC-1\(\alpha\), peroxisome proliferator-activated receptor gamma coactivator 1-\(\alpha\); RPTC, renal proximal tubule cells; SMILES, Simplified Molecular Input Line Entry Specification; SRT1720, N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; TBHP, t-butylhydroperoxide; TC, tanimoto coefficient; XF-96, Seahorse Biosciences extracellular flux analyzer.

Recommended Section Assignment: Drug Discovery and Translational Medicine
Abstract

Mitochondrial dysfunction is a common mediator of disease and organ injury. While recent studies show that inducing mitochondrial biogenesis (MB) stimulates cell repair and regeneration, only a limited number of chemicals are known to induce MB. To examine the impact of the β-adrenergic receptor (β-AR) signaling pathway on MB, primary renal proximal tubule cells (RPTC) and adult feline cardiomyocytes (AFC) were exposed for 24 hours to multiple β-AR agonists: isoproterenol (non-selective β-AR agonist), BRL 37344 (selective β3-AR agonist), and formoterol (selective β2-AR agonist). The Seahorse Biosciences Extracellular Flux (XF) analyzer was used to quantify FCCP-uncoupled oxygen consumption rate (OCR), a marker of maximal electron transport chain activity. Isoproterenol and BRL 37244 did not alter mitochondrial respiration at any concentrations examined. Formoterol exposure resulted in increases in both FCCP-uncoupled OCR and mitochondrial DNA (mtDNA) copy number. The effect of formoterol on OCR in RPTC was inhibited by the β-AR antagonist propranolol and the β2-AR inverse agonist ICI118,551. Mice exposed to formoterol for 24 or 72 h exhibited increases in kidney and heart mtDNA copy number, PGC-1α, and multiple genes involved in the mitochondrial electron transport chain (ATP6, ND1, ND6, and NDUFB8). Cheminformatic modeling, virtual chemical library screening, and experimental validation identified nisoxetine from the Sigma Library of Pharmacologically Active Compounds, and two compounds from the ChemBridge DIVERSetTM that increased mitochondrial respiratory capacity. These data provide compelling evidence for the use and development of β2-AR ligands for therapeutic MB.
Introduction

Mitochondrial dysfunction is associated with the etiology of multiple diseases including Alzheimer's disease, Parkinson's disease, diabetes, as well as renal, liver and myocardial injury (Hagen et al., 2002; Baloyannis, 2006; Civitarese and Ravussin, 2008; Seo et al., 2010; Tran et al., 2011). Mitochondrial dysfunction is also a common cause and consequence of ischemia/reperfusion, trauma, and drug/toxicant-induced organ injury. In ischemic/reperfusion and lipopolysaccharide induced acute kidney injury (AKI), there is a persistent loss of mitochondrial function (Funk et al., 2010; Tran et al., 2011). Mitochondrial damage may hinder critical energy-dependent repair mechanisms and lead to irreversible cell injury, limiting restoration of organ function. Thus, the development of therapies to promote mitochondrial biogenesis (MB) has the potential to treat multiple pathologies and restore organ function after injury.

Mitochondria are constantly being renewed through the processes of biogenesis, fusion, fission, and mitophagy (Seo et al., 2010). MB occurs under homeostatic conditions, and can be induced as an adaptive response initiated by cells to meet energetic demands resulting from injury, genetic, metabolic, and dietary events, thereby impacting health and disease (Medeiros, 2008). MB is a complex process requiring the coordination of both nuclear and mitochondrial DNA (mtDNA) that encode for mitochondrial proteins. A primary regulator of MB is the nuclear transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α). PGC-1α interacts with cAMP response element-binding protein and nuclear respiratory factors 1 and 2 to regulate the transcription of multiple genes (Wu et al., 2006). PGC-1α provides a direct link between external physiological stimuli and the regulation of MB, and is inducible both physiologically and pharmacologically.
There are a limited number of chemicals known to induce MB. The Spiegelman group conducted a high-throughput screen that examined the effects of 3,000 compounds in skeletal muscle cells and 82 compounds (2.5%) increased PGC-1α mRNA (Arany et al., 2008). More recently, our laboratory reported that isoflavones, a 5HT2 agonist (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride; DOI), and a SIRT1 activator (N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; SRT1720) induce MB in renal proximal tubular cells (RPTC) (Rasbach and Schnellmann, 2008; Funk et al., 2010; Rasbach et al., 2010). Furthermore, we determined that stimulation of MB after the initiation of cellular injury accelerates cell repair and regeneration. For example, after t-butylhydroperoxide (TBHP) induced oxidant injury, exposure of primary cultures of RPTC to DOI, SRT1720 or over expression of PGC1-α accelerated recovery of mitochondrial and ATP-dependent cellular functions (Rasbach and Schnellmann, 2007; Funk et al., 2010; Rasbach et al., 2010). Therefore, targeted stimulation of MB may be a valuable approach in the development of new therapies for the treatment of injury and disease characterized by mitochondrial impairment (Funk et al., 2010).

Agonists for the β2-AR have been reported to modulate oxidative metabolism, energy expenditure, lipolysis, glucose transport, and glucose oxidation (Agbenyega et al., 1995; Hagstrom-Toft et al., 1998; Pearen et al., 2008). Pearen et al.(2009), found that mice dosed with the β2-AR agonist formoterol, showed a 5-fold mRNA induction of PGC1-α in skeletal muscle. Additionally, exercise-induced increase in PGC-1α mRNA was inhibited by pretreatment with the β2-AR inverse agonist ICI 118,551 and the β-AR antagonist propranolol, suggesting that β-AR activation mediates exercise-induced increases in PGC-1α in skeletal muscle (Miura et al., 2007; Sutherland et al., 2009). Thus, stimulation of the β2-AR signaling pathway may regulate mitochondrial function in multiple tissues.
β-AR receptor agonists are approved therapeutic agents for the management of asthma and other diseases. The β2-AR has been successfully targeted for drug discovery using a ligand-based approach, resulting in the creation of multiple receptor-specific drugs (Wishart et al., 2006). Recently, Kolb et al. (2009), used the X-ray structure of the β2-AR to conduct a structure-based screen of nearly one million commercially available molecules. Utilizing the β2-AR crystallized in complex with the inverse agonist carazolol, the researchers identified 25 novel compounds that fit the receptor, and six of the compounds were confirmed as inverse agonists. However, the therapeutic potential of β2-AR agonists as inducers of MB has not fully been explored (Ortega and Peters, 2010).

In this study we use a unique phenotypic approach recently developed by Beeson et al. (2010), to examine the potential of β2-AR agonism to induce MB in both the kidney and the heart. The Seahorse Biosciences extracellular flux analyzer was used to evaluate the effects of β2-AR agonists on maximal mitochondrial respiration in primary cultures of RPTC and cardiomyocytes, two cells highly dependent on aerobic metabolism. *In vivo* and ligand-based *in silico* studies were then employed to integrate the effects of β2-AR agonists on mitochondrial function and gene expression, with detailed analysis of chemical structure. These data were used to develop a discrete pharmacophore model capable of predicting novel compounds with MB properties.

**Methods**

All experiments were performed in accordance with the national and institutional guidelines for animal welfare, adhering to protocols approved by the institutional subcommittee on research animal care.

**Chemistry**
All solvents and reagents, unless otherwise stated, were supplied by Sigma-Aldrich Chemical Co. Ltd. and were used as supplied.

(±)-(R*,R*)-[4-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy] acetic acid sodium hydrate (BRL 37344), (R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]pheny]formamide fumarate (formoterol fumarate dihydrate), and (R)-3,4-Dihydroxy-α-(isopropylaminomethyl)benzyl alcohol hydrochloride (isoproterenol hydrochloride) were purchased from Sigma-Aldrich Chemical Co. Ltd. and were confirmed to be 98% pure by HPLC. The Library of Pharmacologically Active Compounds (LOPAC) was purchased from Sigma-Aldrich Chemical Co. Ltd. and the compounds were confirmed to be 95% pure by HPLC. The ChemBridge DIVERSet™ 50,000 compound library was purchased from ChemBridge Corporation and the compounds were confirmed to be 95% pure by HPLC.

**Biological Evaluation of Compounds**

**Isolation of proximal tubules.** Female New Zealand white rabbits (1.5-2.0 kg) were purchased from Myrtle's Rabbitry (Thompson Station, TN, USA). Rabbit renal tubules were isolated using the iron oxide perfusion method as described in Nowak et al. (1995). The resulting proximal tubules were plated on 100-mm tissue culture-grade plastic Petri dishes constantly swirled on an orbital shaker at 80 rpm. The culture medium was a 50:50 mixture of Dulbecco's modified Eagle's essential medium and Ham's F12 (lacking glucose, phenol red, and sodium pyruvate; Gibco BRL) supplemented with 5 μg/ml human transferrin, 5 ng/ml selenium, 50 nM hydrocortisone, and 10 nM bovine insulin. After three days the de-differentiated cells were trypsinized and re-plated onto XF-96 polystyrene cell culture microplates at a concentration of 18,000 cells/well and maintained in a 37°C incubator for two days prior to experimentation (Beeson et al., 2010).

**Isolation of primary adult feline cardiomyocytes.** Adult feline cardiomyocytes were isolated to 95% purity as published previously (Mann et al., 1989). In the present study,
we used glass-bottom dishes (MatTek) coated with laminin for culturing cardiomyocytes in Piper’s medium, which was prepared in M199 cell culture medium (Invitrogen) containing the following additional ingredients: 2% bovine serum albumin, 5 mM creatine, 2 mM L-carnitine, 5 mM taurine, 0.25 mM L-ascorbate, 10 μM cytosine arabinoside, 200 units/ml penicillin and 200 mg/ml streptomycin (Invitrogen). The freshly isolated adult cardiomyocytes were plated into XF-96 Polystyrene Cell Culture Microplates and were maintained in a 37°C incubator for two days prior to experimentation.

**Respirometry assay.** The OCR measurements were performed using a Seahorse Bioscience XF-96 instrument according to the protocol outlined in Beeson et al. (2010). Each experimental plate was treated with vehicle controls (DMSO < 0.5%), a positive control (SRT1720, 10 μM), blank controls, and the appropriate concentration of the compound of interest. The XF-96 protocol consists of five measurements of basal OCR (1 measurement/ 1.5 min), injection of FCCP (0.5 μM), and three measurements of uncoupled OCR (1 measurement/ 1.5 min). The consumption rates were calculated from the continuous average slope of the O₂ partitioning among plastic, atmosphere, and cellular uptake (Gerencser et al., 2009). Quality control evaluations considered the basal and uncoupled rates of the vehicle control, positive control, and variances between duplicate treatment wells. Based on preliminary studies the positive threshold value was > 1.15 for the mean ratio of (chemical treatment FCCP-OCR/vehicle control FCCP-OCR). This threshold is ≥ 1 S.D. above the historic mean for the vehicle control.

**Dosing of C57BL/6 mice.** Male C57BL/6 mice (NCI) were between six and eight weeks old. The mice were housed in groups of three in a temperature-controlled room, under a 12/12 h light/dark cycle. Mice were randomly assigned to either saline control or formoterol treated groups (n=3-6 mice/group). Treated mice received daily i.p. injections of formoterol for up to 72 h (100 μg/kg/day) and control mice received an equivalent volume of sterile saline.
Real time RT-PCR. Total RNA was isolated from renal cortex and heart using TRIzol reagent (Invitrogen). cDNA was synthesized from 2 μg of RNA template using SuperScript II Reverse Transcriptase kit (Invitrogen). PCR products were amplified from 5 μl of cDNA template in a 25 μl reaction containing 12.5 μl of 2x SYBR Premix (Stratagene) and 400 nM of each primer (Integrated DNA Technologies) (Supplemental Table 1). The average fold induction was calculated by comparing the C_T (threshold cycle) of the target gene to that of tubulin (the reference gene). The gene expression of the reference gene remained consistent throughout each treatment. The C_T of each of the technical replicates was averaged, and that average was used in the following formulas:

\[
C_T \text{ (target gene)} - C_T \text{ (β-actin)} = ΔC_T \\
ΔC_T \text{ (treatment)} - ΔC_T \text{ (control)} = ΔΔC_T \\
2^{(-ΔΔC_T)} = \text{fold change}
\]

Mitochondrial DNA Content. Real-time PCR was used to determine relative quantities of mtDNA content in both RPTC and mouse kidney and heart tissues. Genomic DNA was extracted using the DNeasy Blood and Tissue kit (QIAGEN, Valencia, CA). PCR products were amplified from 25 ng of cellular DNA in a 25 μl reaction containing 12.5 μl of 2x SYBR Premix and 400 nM of each primer. For estimation of mtDNA in RPTC the ND6 gene was amplified. The nuclear-encoded tubulin gene was used for normalization (Supp. Table 1). For estimation of mtDNA in mice the control region (D-loop) of mouse mtDNA was amplified. The nuclear-encoded apoB gene was used for normalization (Supplemental Table 1) (Fuke et al., 2011).

Computational Procedures

Molecular modeling of potential mitochondrial biogenic compounds. Modeling, simulations and visualizations were performed using MOE Version 2010.10 (Chemical Computing Group Inc.). The Sigma LOPAC and the ChemBridge DiverSet™ were searched using the Tanimoto score with MACCS structural keys (166 keys).
fingerprinting (*Maccs II*; Molecular Design Ltd.). Using tables of the compounds represented as Simplified Molecular Input Line Entry Specification (SMILES) strings were imported into MOE as an mdb database. Molecules were rigidly aligned manually, and then subjected to MOE flexible body refinement (configuration limit 100, alpha 1, gradient test 0.01, RMSD tolerance 0.5, maximum steps 500). The ChemBridge DIVERSet™ conformers were a stochastic force field based library generated using MOE conformation import with no import filters. Total number of possible conformations per molecule was 50 and used default settings including a strain limit of 4 kcal/mol, RMSD test for structural diversity of 0.15, trans conformations were enforced, and an energy minimization gradient test of 0.01 kcal/mol. Consensus pharmacophores were calculated using a distance parameter (tolerance) maintained at the default value of 1.2 angstroms and a threshold of 100%. Pharmacophore feature projections including aromatic ring projections (PiN), H-bond acceptor projections (Don2), and H-bond acceptor projections (Acc2) were not included in the analysis.

**Statistical Analysis.** Data are presented as means ± s.e.m. and were tested for normality. Data that was confirmed to have a normal distribution were subjected to one-way analysis of variance (ANOVA). The respiration data failed a normality test, therefore a Kruskal-Wallis one-way ANOVA on ranks was conducted. Multiple means were compared utilizing Dunn’s post hoc test and were considered statistically different when \( P<0.05 \). RPTCs and AFCs isolated from a single animal represented an individual experiment (\( N=1 \)) and were repeated until an \( N \geq 4 \) was obtained. Rodent studies were repeated until an \( N \geq 3 \) was obtained.

**Results**

\( \beta_2 \)-adrenergic agonist induces MB *in vitro*

Kidney proximal tubules require aerobic metabolism to maintain high levels of ATP for transport processes. The primary cultures of RPTC utilized in this study were
grown under improved culture conditions with optimized glucose-free media supplemented with 6 mM sodium lactate, and increased oxygen supply (Nowak and Schnellmann, 1995; Nowak and Schnellmann, 1996). RPTC grown under these conditions remain polarized, maintain their differentiated functions, and exhibit respiration and gluconeogenesis rates comparable to in vivo renal proximal tubule cells. The primary culture of adult feline cardiomyocytes (AFC) utilized in the study also maintain differentiated function and exhibit mitochondrial respiration similar to that observed in vivo (Mitcheson et al., 1998).

Primary cultures of RPTC and AFC have been optimized for use with the Seahorse Biosciences 96-well extracellular flux analyzer (XF-96), a multi-well plate-based assay platform that addresses the need for higher throughput cellular respirometric measurements (Beeson et al., 2010; Ferrick et al., 2008). The XF-96 instrument uses fluorescent detectors to measure oxygen consumption rates (OCR), and can be used to identify compounds that alter mitochondrial respiration. Injection of the proton ionophore carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) uncouples the mitochondrial membrane potential from the production of ATP increasing the OCR. We determined that this maximum respiratory capacity could be used as a measure of MB (Beeson et al., 2010).

The FCCP-OCR increased in RPTC after a 24 hr exposure to formoterol (30 nM) relative to the vehicle control (Fig.1A). The FCCP-uncoupled OCR was also increased in AFC after a 24 hr exposure to formoterol (10 and 30 nM) (Fig.1B). No significant changes in FCCP-OCR were observed after exposure to isoproterenol (non-selective β-AR agonist; 10, 100, 1000 nM) or BRL 37344 (selective β3-AR agonist; 100, 300, 1000 nM). The catecholamines dopamine, epinephrine, and norepinephrine are non-selective agonists for all three of the β-adrenoceptors (Hall et al., 1990). No significant changes in FCCP-OCR were observed in the RPTC after exposure to dopamine, epinephrine, or norepinephrine (30 and 100 nM) (Fig. 1C).
To further document that the increased OCR values were the result of MB, mitochondrial DNA (mtDNA) copy number was assessed. Relative mitochondrial DNA copy number was determined using quantitative real-time PCR and the ratio of a mitochondrial-encoded gene (NADH dehydrogenase subunit 6, ND6) to a nuclear-encoded gene (tubulin). Formoterol (30 nM) treated cells exhibited a significant 2.5-fold increase in mitochondrial copy number (Fig. 1D). These results provide strong evidence that β₂-adrenergic receptor activation induces MB in RPTC and AFC and that formoterol is a potent agonist.

β₂-adrenergic agonist induces MB in vivo

To determine whether β₂-AR agonism in vivo produces MB, male C57BL/6 mice were dosed intraperitonealy (i.p.) with 100 μg/kg formoterol every day for 1 or 3 days. Kidney and heart tissues were collected from the animals and MB was determined by assessing mitochondrial DNA copy number and the mRNA levels of multiple mitochondrial proteins.

Twenty-four hr after formoterol exposure, mRNA levels of multiple genes involved in mitochondrial regulation and function increased in kidneys. PGC-1α was induced 2.5-fold and mitochondrially-encoded ATP synthase F0 subunit 6 of transmembrane F-type ATP synthase (ATP6), ND1, and ND6 were induced 2.5-, 4- and 2.5-fold, respectively (Fig. 2A). The kidneys of formoterol exposed animals also showed 2-fold induction of the nuclear-encoded mitochondrial protein NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8 (NDUFB8). After repeated daily exposure to 100 μg/kg formoterol for 72 hr, the kidneys exhibited 1.5-fold induction of PGC-1α, as well as a 2-fold induction of NDUFB8 and ND1 (Fig. 2B). The mtDNA copy number was increased in the kidneys of mice 72 h after repeated daily formoterol exposures (Fig. 2C).
The hearts of mice exposed to 100 μg/kg formoterol for 24 hr exhibited a marked induction of PGC-1α, ATP6, ND1, ND6, and NDUFB8 (3-, 1.5-, 2-, 2- and 2-fold, respectively) (Fig. 3A). After a repeated daily exposure to 100 μg/kg formoterol for 72 hr, the hearts of formoterol exposed animals exhibited 2-fold induction of PGC-1α, a 4-fold induction of mitochondrially-encoded ND1, and a 2-fold induction of nuclear-encoded NDUFB8 (Fig. 3B). The mtDNA copy number was increased in the hearts of mice 24 and 72 h after daily formoterol exposures (Fig. 3C). These results provide strong evidence that β2-adrenergic receptor activation induces MB in the kidney and heart.

**Formoterol-based pharmacophore identifies novel mitochondrial biogenics**

Using formoterol as a basis for chemical similarity and pharmacophore analysis, we explored chemical space that would otherwise be impractical to explore given current limitations in biological assay techniques. Pharmacophores are defined as a collection of steric and electronic features required for molecular interactions with a specific biological target structure, resulting in the activation or deactivation of its biological response (Horvath, 2011). Pharmacophore models have been developed to identify biologically active chemicals responsible for therapeutic activity (Ebalunode et al., 2011). The resulting structures can be used to predict potential pharmacology based on the assumption that compounds containing the same pharmacophore are likely to cause similar effects by targeting the same active site (Horvath, 2011). Currently, there are no known pharmacophores associated with MB. We utilized formoterol in a ligand-based approach to identify novel compounds with a similar chemical structure and determine if they induced MB.

We used formoterol to conduct a similarity search of the 1280 compound Sigma Library of Pharmacologically Active Compounds (LOPAC). Similarity was measured using the Tanimoto Coefficient (TC). TC is a similarity metric of one-dimensional
chemical descriptors that identifies the presence of molecular elements, and facilitates rapid initial comparisons (Willett, 2006). A TC similarity search of LOPAC found 23 compounds 60% similar to formoterol. RPTC were treated with the 23 identified LOPAC compounds (5 μM) for 24 hr and examined for changes in FCCP-uncoupled OCR. This assay revealed that nisoxetine increases FCCP-uncoupled OCR above vehicle control (Table 1). A subsequent concentration response evaluation determined that nisoxetine increased FCCP-uncoupled OCR in a concentration-dependent manner, with a minimum effective dose of 30 nM (Fig. 4A).

To confirm the specificity of formoterol on β2-AR, we pretreated cells for 1 hr with the β-AR antagonist propranolol (5 nM) or the β2-AR inverse agonist ICI 115,881 (3 and 10 nM) prior to a 24 hr treatment with the formoterol (30 nM). As seen in Fig. 5, both propranolol and ICI 115,881 attenuated the formoterol-induced increase in FCCP-OCR in RPTC. Nisoxetine is a norepinephrine reuptake inhibitor and there is no direct published data suggesting nisoxetine activates β2-AR. Nevertheless, because there is a report that some effects of nisoxetine are blocked by propranolol (Springer et al., 1994), we determined whether propranolol and ICI 115,881 blocked the MB effects of nisoxetine. Propranolol (5 nM) and ICI 115,881 (3 and 10 nM) blocked the increase in FCCP-OCR produced by nisoxetine (Fig. 5).

Formoterol and nisoxetine were aligned in first two and then three dimensions based on the presence of consensus chemical features within 100% of the compounds. This alignment resulted in a pharmacophore containing six features of conserved chemical similarity (Fig. 4B). F1 is a proton acceptor, F2 and F3 are hydrophobic, F4 is a mixed feature with a cationic and proton donor, and F5 and F6 are mixed features with aromatic and hydrophobic characteristics. Distances (in Å) of the model are F1-F2: 2.53, F2-F4: 2.02, F4-F3: 1.77, F3-F5: 4.55, F5-F6: 6.56, and F6-F4: 4.76.

The 6-point pharmacophore model was used to search the ChemBridge DIVERSet™ for similar compounds. This library contains 50,080 unique drug-like
compounds that represent a wide range of chemical diversity. These compounds were used to create a 1,420,467 entry conformer library. An in silico search identified 16 compounds containing all six chemical features with a RMSD < 1 Å. No compounds with an RMSD > 1 Å were identified, but this was expected as each feature is only ~1 Å in diameter and six features were absolutely required leading to a minimum possible RMSD. Note that the TC search and pharmacophore search of ChemBridge have no overlapping compounds.

RPTC were exposed to the 16 identified ChemBridge compounds (5 μM) for 24 hr and examined for changes in FCCP-OCR. This assay identified three novel compounds (CB1-3) that increase FCCP-OCR above the vehicle control (Table 2). In a previous study our laboratory tested 480 random compounds from the ChemBridge DIVERSet™ on the XF-96. From these 480 random compounds, thirteen were determined to be biogenic (unpublished data). We extrapolate that the spontaneous hit rate of the entire data set would be approximately 2.7%. Our pharmacophore performed with a hit rate of 18.8% of the compounds it chose. Using the enrichment factor equation from Pearlman and Charifson (2001), our pharmacophore selected a subset of the database 6.9 times richer in biogenic compounds than the original database.

\[ EF = \frac{HIT_{sampled-set}}{N_{sampled-set}} / \frac{HIT_{total-database}}{N_{total-database}} \]

RPTC were exposed for 24 h to 10-3000 nM of CB1, CB2, and CB3 to determine potency in increasing FCCP-OCR. CB2 and CB3 increased FCCP-OCR in RPTC with maximal effects at 30 and 100 nM respectively, while CB1 was not effective at this concentration range (Fig. 6A). These data were incorporated into the original model and used to further refine the pharmacophore. Formoterol, nisoxetine, CB2 and CB3 were aligned in both two and three dimensions and matched all six of the original features suggesting the model accurately described all of the essential features (Fig. 6B). Analysis of the final alignment revealed a unique hydrophobic feature (F7) found in nisoxetine, and CB2 (Fig. 6C, Table 3).
Discussion

The mitochondrion is an intricate organelle, with components derived from both the nuclear and mitochondrial genomes, whose activity must be carefully coupled to cellular metabolism and signaling (Wagner et al., 2008). Mitochondrial health is essential for cell and organ function. Multiple diseases are characterized by mitochondrial impairment including diabetes, Alzheimer’s disease, Parkinson’s disease and diet-induced obesity. Ischemia/reperfusion injury of the kidney, heart and liver all show deleterious consequences on mitochondrial function. Therefore, the development of novel pharmaceuticals that induce MB may have broad usage in diverse diseases.

Despite the potential for treating disorders characterized by mitochondrial impairment, very few therapies target the mitochondria to promote its function (Funk et al., 2010). Likewise, there are no current databases matching mitochondrial biogenic activity to chemical pharmacophores or specific chemotypes. Those studies that have focused on MB as a therapeutic target have used skeletal muscle cells and assay systems using surrogate markers of MB (e.g. PGC-1α mRNA). Surrogate markers may suffer from false-positives and negatives, and the use of cell lines that are highly glycolytic with limited aerobic capacity may not be sensitive to MB. The use of primary cultures of primary RPTC grown under improved conditions resolves the cell line issue and the use of a phenotypic respirometric assay minimizes the limitations of surrogate markers.

We demonstrate that formoterol, a potent and selective agonist for the β2-AR, stimulates MB in both RPTC and AFC within 24 hr of a 30 nM exposure (Fig. 1). Neither a selective β3-AR agonist (BRL 37344) nor non-selective β-AR agonists (dopamine, epinephrine, norepinephrine, or isoproterenol) stimulate MB in RPTC. Additionally the ability of formoterol to increase FCCP-OCR was inhibited by the β-AR antagonist
Researchers have showed that exercise-induced increases in PGC-1α mRNA in skeletal muscle, is blocked by the β2-AR inhibitor ICI 118,551 and β-AR inhibitor propranolol (Miura et al., 2007; Sutherland et al., 2009). Additionally PGC-1α in skeletal muscle 24 hr increased after injection of formoterol (100 μg/kg) (Pearen et al., 2009). In our studies, the same dose of formoterol induced MB in the kidney and heart of male mice as indicated by increased mRNA expression of multiple mitochondrial proteins that are both nuclear and mitochondrially-encoded (NDUFB8, AT6, ND1, ND6) (Fig. 2-3). Furthermore, PGC1-α, the master regulator of MB, was induced both 24 and 72 h after formoterol exposure. Using the aforementioned markers of MB, these data suggest that formoterol does induce MB in vivo and in both the kidney and the heart.

We utilized the chemical structure of formoterol to search the Sigma LOPAC of 1280 compounds to find current pharmacological compounds that were similar in structure to formoterol and therefore may induce MB. We identified 29 compounds that were tested for their ability to increase the FCCP-OCR in RPTC after a 24 h 5 μM exposure. We identified nisoxetine as a potent inducer (30-300 nM) of MB. Nisoxetine is reported to be a potent and selective inhibitor of noradrenaline uptake with little or no affinity for a range of other similar neurotransmitter receptors (Wong and Bymaster, 1976; Cheetham et al., 1996; Mochizucki, 2004). Currently there are no data suggesting a role for nisoxetine in inducing MB. Interestingly nisoxetine was aligned with formoterol and a preliminary pharmacophore was developed with six features in common (Fig. 4B). Additionally, propranolol and ICI 118,551 blocked the MB effects of both compounds (Fig. 5). These data provide strong evidence that nisoxeteine is an agonist at the β2 AR receptor.
In addition to finding pharmacologically active compounds with MB activity, we utilized the formoterol-based pharmacophore to probe diverse chemical space. The pharmacophore designed from formoterol and nisoxetine was used to screen the 50,000 small molecule ChemBridge DIVERSet™. The in silico screen identified only 16 compounds that matched all six chemical features that defined the pharmacophore. When tested utilizing RPTC, three of the compounds (19% accuracy in prediction, enrichment factor of 6.9) increased FCCP-OCR 24 h after a 5 μM exposure. A concentration response curve for the three compounds revealed CB2 and CB3 increased MB at 30 nM while CB1 had no effect at concentrations below 5 μM. The positive compounds were aligned, resulting in the development of a refined pharmacophore with six features present within 100% of the compounds (Fig. 6B). Negative data are not included as no clear consensus to exclusion space was reached. This improved pharmacophore can be used to search libraries such as the World Drug index to find other compounds that match the pharmacophore and induce MB. In addition, future studies will attempt to identify a broader range of novel agonists for β2-AR mediated MB by utilizing a structure-based approach of the β2-AR as outlined by Kolb et al (2009).

There is an abundance of evidence showing that exercise induces MB in skeletal muscle, and recent data suggests that β-AR agonism is required for exercise-mediated alterations in mitochondrial function (Miura et al., 2007; Higashida et al., 2008; Sutherland et al., 2009; Little et al., 2011). However, the potential use for β2-AR agonists for the treatment of mitochondrial dysfunction and injury has not yet been explored. Although evidence suggests that chronic exposure to formoterol does decrease oxidative capacity in the heart, acute exposures to β2-AR agonists do have the potential to activate MB after insult with limited detrimental effects (Ortega and Peters, 2010; Léger et al., 2011). Agonists for the β2-AR are promising therapeutics for the treatment
of mitochondrially-related organ dysfunction found in diseases including diabetes, as well as to promote recovery after injury, including acute kidney injury. We have identified a role of formoterol in the induction of MB in both the kidney and the heart. Additionally we have utilized the chemical structure of formoterol to identify four new mitochondrial biogenic compounds. Future studies will focus on the potential of formoterol exposure to promote recovery of kidney and heart mitochondrial function in both disease and injury models.
Acknowledgments: We would like to acknowledge the MUSC Drug Discovery Core for access to the ChemBridge DIVERSet™ and the MUSC/Seahorse Biosciences Academic Core Facility.

Contributions:

Participated in research design: Wills, Schnellmann, C.C. Beeson, and Peterson. 
Conducted experiments: Wills, G.C. Beeson, and Trager.
Contributed new reagents or analytic tools: Peterson.
Performed data analysis: Wills, Trager, Peterson, Lindsey, and C.C. Beeson.
Wrote or contributed to the writing of the manuscript: Wills, Trager, Peterson, and Schnellmann.
References


LPW is funded by the National Institutes of Health grant T32 CA119945-04 and F32 ES020103-01. RGS is funded by the National Institutes of Health grants DK062028, ES012878, DK071997, and GM084147 and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. Animal facilities were funded by NIH grant [C06 RR-015455].

Portions of this work have been presented previously: Wills LP, Trager RE, Beeson GC, Lindsey CC, Peterson YK, Beeson CC, Schnellmann RG (2011) Characterization of a β₂ Adrenoceptor pharmacophore that predicts mitochondrial biogenesis; at the American Society of Nephrology Annual Meeting, 2011 November 8-13; Philadelphia, PA.
Legends for Figures

**Fig. 1.** Formoterol exposure increases uncoupled oxygen consumption rate and mtDNA copy number in RPTC and AFC. A, RPTC exposed to isoproterenol (non-specific $\beta$-AR agonist), BRL 37344 ($\beta_3$-AR agonist), and formoterol ($\beta_2$-AR agonist) for 24 hr and evaluated for changes in FCCP-OCR. B, AFC exposed to isoproterenol (non-specific $\beta$-AR agonist), BRL 37344 ($\beta_3$-AR agonist), and formoterol ($\beta_2$-AR agonist) for 24 hr and evaluated for changes in FCCP-OCR. C, RPTC exposed to the non-specific $\beta$-AR agonists dopamine, epinephrine, and norepinephrine for 24 hr and evaluated for changes in FCCP-OCR. D, RPTC exposed to 30 nM formoterol for 24 hr and evaluated for changes in mtDNA copy number relative to DMSO controls. Data are represented as mean $\pm$ s.e.m. of four biological replicates (* $P < 0.05$).

**Fig. 2.** Formoterol exposure induced the expression of mitochondrial genes and mtDNA copy number in the kidney cortex of CB57BL/6 mice. A, mRNA expression evaluated in the kidney cortex of CB57BL/6 mice 24 hr after a single i.p. injection with 100 $\mu$g/kg formoterol. B, mRNA expression evaluated in the kidney cortex of CB57BL/6 mice 72 hr after daily repeated i.p. injections with 100 $\mu$g/kg formoterol. C, mtDNA copy number evaluated in the kidney cortex 24 hr and 72 hr after daily repeated i.p. injection with 100 $\mu$g/kg formoterol. Values indicate fold change relative to DMSO controls. Data are represented as mean $\pm$ s.e.m. of three- six biological replicates (* $P < 0.05$).

**Fig. 3.** Formoterol exposure induced the expression of mitochondrial genes and mtDNA copy number in the heart of CB57BL/6 mice. A, mRNA expression evaluated in the hearts of CB57BL/6 mice 24 hr after a single i.p. injection with 100 $\mu$g/kg formoterol. B, mRNA expression evaluated in the hearts of CB57BL/6 mice 72 hr after daily repeated i.p. injections with 100 $\mu$g/kg formoterol. C, mtDNA copy number evaluated in the heart
24 hr and 72 hr after daily repeated i.p. injection with 100 μg/kg formoterol. Values indicate fold change relative to DMSO controls. Data are represented a mean ± s.e.m. of three to six biological replicates (* P < 0.05).

**Fig. 4.** Cheminformatic analysis of formoterol identified nisoxetine which induces MB in RPTC. A, RPTC exposed to formoterol and nisoxetine (10-300 nM) for 24 hr and examined for changes in FCCP-OCR. B, pharmacophore based on alignment of formoterol and nisoxetine. Formoterol and nisoxetine aligned with superimposed chemical features. F1 is a proton acceptor, F2 and F3 are hydrophobic, F4 is a mixed feature with a cationic and proton donor, and F5 and F6 are mixed features with aromatic or hydrophobic characteristics. F1 and F4 were marked as essential while requiring that at least 5 features matched the model. C, formoterol aligned with superimposed pharmacophore. Values indicate a percent of fold change relative to DMSO controls. Data are represented a mean ± s.e.m. of four biological replicates (* P < 0.05).

**Fig. 5.** The effects of formoterol and nisoxetine are inhibited by β2 antagonism. A, RPTC pre-exposed to the β-AR antagonist propranolol (5 nM) one hr prior to exposure to 30 nM formoterol or nisoxetine and evaluated for changes in FCCP-OCR. B, RPTC pre-exposed to the β2-AR inverse agonist ICI 118,551 (3 and 10 nM) one hr prior to exposure to 30 nM formoterol or nisoxetine and evaluated for changes in FCCP-OCR. Values indicate a percent of fold change relative to DMSO controls. Data are represented a mean ± s.e.m. of four biological replicates (* P < 0.05).

**Fig. 6.** Formoterol pharmacophore identified two ChemBridge compounds that induce MB in RPTC. A, RPTC exposed to ChemBridge compounds 1-3 (10-300 nM) for 24 hr and evaluated for changes in FCCP-OCR. B, refined pharmacophore based on
JPET #191528

alignment of formoterol, nisoxetine, CB2 and CB3. In this alignment, F1 is a proton acceptor, F2 through F3 are hydrophobic, F4 is a mixed feature with a proton donor and a cationic or proton acceptor, and F5 and F6 are mixed features with aromatic or hydrophobic characteristics. F7 is a unique hydrophobic feature found in nisoxetine and CB2. F1, F2, F4, F5, and F6 are essential features. C, nisoxetine aligned with superimposed pharmacophore. Values indicate a percent of fold change relative to DMSO controls. Data is represented a mean ± s.e.m. of four biological replicates.
Table 1

<table>
<thead>
<tr>
<th>Structure</th>
<th>Name</th>
<th>Average uncoupled OCR ratio</th>
<th>CAS number</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Nisoxetine structure" /></td>
<td>Nisoxetine</td>
<td>1.2±0.08</td>
<td>57754-86-6</td>
</tr>
<tr>
<td><img src="image2.png" alt="Olvanil structure" /></td>
<td>Olvanil</td>
<td>1.12±0.08</td>
<td>58493-49-5</td>
</tr>
<tr>
<td><img src="image3.png" alt="Dihydrocapsaicin structure" /></td>
<td>Dihydrocapsaicin</td>
<td>1.12±0.1</td>
<td>19408-84-5</td>
</tr>
<tr>
<td><img src="image4.png" alt="Mitoxantrone structure" /></td>
<td>Mitoxantrone</td>
<td>1.1±0.06</td>
<td>65271-80-9</td>
</tr>
<tr>
<td><img src="image5.png" alt="Carvedilol structure" /></td>
<td>Carvedilol</td>
<td>1.09±0.03</td>
<td>72956-09-3</td>
</tr>
<tr>
<td><img src="image6.png" alt="GR 55562 structure" /></td>
<td>GR 55562</td>
<td>1.09±0.09</td>
<td>159533-26-3</td>
</tr>
<tr>
<td><img src="image7.png" alt="Dobutamine structure" /></td>
<td>Dobutamine</td>
<td>1.09±0.14</td>
<td>49745-95-1</td>
</tr>
<tr>
<td><img src="image8.png" alt="SR 59230A structure" /></td>
<td>SR 59230A</td>
<td>1.09±0.07</td>
<td>174689-39-5</td>
</tr>
<tr>
<td><img src="image9.png" alt="(-)-Normetanephrine structure" /></td>
<td>(-)-Normetanephrine</td>
<td>1.06±0.03</td>
<td>1011-74-1</td>
</tr>
<tr>
<td>Compound</td>
<td>Value ± SD</td>
<td>CAS Number</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Ranolazine</td>
<td>1.03±0.03</td>
<td>95635-56-6</td>
<td></td>
</tr>
<tr>
<td>(-)-Epinephrine</td>
<td>1.03±0.1</td>
<td>51-42-3</td>
<td></td>
</tr>
<tr>
<td>Ritodrine</td>
<td>1.02±0.09</td>
<td>23239-51-2</td>
<td></td>
</tr>
<tr>
<td>Metaproterenol</td>
<td>1.02±0.06</td>
<td>586-06-1</td>
<td></td>
</tr>
<tr>
<td>Fenoterol</td>
<td>0.98±0.04</td>
<td>12/3/1944</td>
<td></td>
</tr>
<tr>
<td>S(-)-Atenolol</td>
<td>0.98±0.12</td>
<td>93379-54-5</td>
<td></td>
</tr>
<tr>
<td>L-3,4-Dihydroxyphenylalanine methyl ester</td>
<td>0.95±0.07</td>
<td>7101-51-1</td>
<td></td>
</tr>
<tr>
<td>(±)-Epinephrine</td>
<td>0.92±0.03</td>
<td>329-63-5</td>
<td></td>
</tr>
<tr>
<td>(±)-Atenolol</td>
<td>0.92±0.15</td>
<td>29122-68-7</td>
<td></td>
</tr>
<tr>
<td>N-Oleoyldopamine</td>
<td>0.9±0.09</td>
<td>105955-11-1</td>
<td></td>
</tr>
<tr>
<td>Labetalol</td>
<td>0.86±0.11</td>
<td>32780-64-6</td>
<td></td>
</tr>
<tr>
<td>N-Methyldopamine</td>
<td>0.82±0.13</td>
<td>62-32-8</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Formoterol pharmacophore extraction of the 1280 compound Sigma Library of Pharmacologically Active Compounds (LOPAC). Chemical fingerprints defined within the MOE software package were used to cluster compounds based on molecular similarity as measured from the Tanimoto Coefficient (TC). Analysis of the data utilizing a TC of 60% identified 23 compounds out of 1280 (or 1.8%) compounds from LOPAC that matched formoterol based on chemical similarity. RPTC were treated with the 23 identified LOPAC compounds (5 μM) for 24 hr and examined for changes in FCCP-OCR. This assay identified nisoxetine which increases FCCP-OCR 15% above vehicle control. Fold change in FCCP-OCR relative to DMSO controls appears in the bottom left of each compound. CAS numbers appear to the bottom right.
**Table 2**

<table>
<thead>
<tr>
<th>Structure</th>
<th>ID</th>
<th>Average Drug FCCP OCR / Control FCCP OCR</th>
<th>CAS number</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Structure 1" /></td>
<td>CB_3 - 6431725</td>
<td>1.22±0.04</td>
<td>398470-83-2</td>
</tr>
<tr>
<td><img src="image2" alt="Structure 2" /></td>
<td>CB_2 - 5144525</td>
<td>1.22±0.08</td>
<td>300852-45-3</td>
</tr>
<tr>
<td><img src="image3" alt="Structure 3" /></td>
<td>CB_1 - 5144510</td>
<td>1.19±0.08</td>
<td>765894-01-7</td>
</tr>
<tr>
<td><img src="image4" alt="Structure 4" /></td>
<td>5402373</td>
<td>1.14±0.05</td>
<td>329720-38-9</td>
</tr>
<tr>
<td><img src="image5" alt="Structure 5" /></td>
<td>6384391</td>
<td>1.14±0.08</td>
<td>443652-15-1</td>
</tr>
<tr>
<td><img src="image6" alt="Structure 6" /></td>
<td>6434119</td>
<td>1.09±0.03</td>
<td>339228-37-4</td>
</tr>
<tr>
<td><img src="image7" alt="Structure 7" /></td>
<td>6433097</td>
<td>1.09±0.06</td>
<td>42528-76-7</td>
</tr>
</tbody>
</table>
### Table 1: Chemical Structures and Properties

<table>
<thead>
<tr>
<th>Compound</th>
<th>Molecular Weight</th>
<th>pKa</th>
<th>CAS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Structure 1]</td>
<td>5144511</td>
<td>1.08±0.06</td>
<td>314027-94-6</td>
</tr>
<tr>
<td>[Structure 2]</td>
<td>6435349</td>
<td>1.01±0.05</td>
<td>313962-89-9</td>
</tr>
<tr>
<td>[Structure 3]</td>
<td>6632718</td>
<td>1±0.05</td>
<td>377074-32-3</td>
</tr>
<tr>
<td>[Structure 4]</td>
<td>5108436</td>
<td>1±0.11</td>
<td>81084-82-4</td>
</tr>
<tr>
<td>[Structure 5]</td>
<td>5533967</td>
<td>0.99±0.07</td>
<td>309251-09-0</td>
</tr>
<tr>
<td>[Structure 6]</td>
<td>5402374</td>
<td>0.94±0.04</td>
<td>1209049-21-7</td>
</tr>
<tr>
<td>[Structure 7]</td>
<td>5244600</td>
<td>0.92±0.1</td>
<td>70029-33-3</td>
</tr>
<tr>
<td>[Structure 8]</td>
<td>6111462</td>
<td>0.89±0.04</td>
<td>263869-50-7</td>
</tr>
</tbody>
</table>
**Table 2.** The 6-point formoterol pharmacophore model was used to search the
ChemBridge DIVERSet™ for similar compounds. This library contains 50,080 unique
drug-like compounds that cover pharmacophore diversity. These compounds were used
to create a 1,420,467 entry conformer library. An *in silico* search identified 16
compounds (or 0.03%) containing all six chemical features with a RMSD < 1 Å to the
pharmacophore model for all features. RPTC were exposed to the 16 identified
ChemBridge compounds (5 μM) for 24 hr and examined for changes in FCCP-OCR.
This assay identified three novel compounds (CB1-3) that increase FCCP-OCR 15%
above the vehicle control. Fold change in FCCP-OCR relative to DMSO controls
appears in the bottom left of each compound. CAS numbers appear to the bottom right.
Table 3. Formoterol, nisoxetine, and (CB 2) ChemBridge #5144525. The original pharmacophore was built using formoterol and nisoxetine. CB 1-3 were found using the original pharmacophore from a search of the ChemBridge DIVERSet™ 50,000 small molecule conformational library. ChemBridge compounds 2 and 3 were confirmed biogenic; however, CB 2 was the only compound to add features to the pharmacophore model.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Title: $\beta_2$ Adrenoceptor Agonist Formoterol Stimulates Mitochondrial Biogenesis

Lauren P. Wills, Richard E. Trager, Gyda C. Beeson, Christopher C. Lindsey, Yuri K. Peterson, Craig C. Beeson and Rick G. Schnellmann


Ralph H. Johnson VA Medical Center Charleston, SC 29401: R.G.S.
Supplementary Table 1. Primer sequences used for qRT-PCR experiments.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequence 5'-3'</th>
</tr>
</thead>
</table>
| APOB       | **FW:** CGT CGG CTC CAG CAT TCT  
              **REV:** TCA CCA GTC ATT TCT GCC TTT G |
| ATP6       | **FW:** TCC TGC CTC ACT CAT TCA CAC CAA  
              **REV:** AGT GCA GCG CCT CCA ATA AGA TGT |
| D-Loop     | **D1:** CCC AAG CAT ATA AGC TAG TAC  
              **D2:** ATA TAA GTC ATA TTT TGG GAA CTA C |
| ND1        | **FW:** TAG AAC GCA AAA TCT TAG GG  
              **REV:** TGC TAG TGT GAG TGA TAG GG |
| ND6        | **FW:** ACT GCG ATG GCA ACT GAG GAG TAT  
              **REV:** ACC ATA ACT ATA CAA CGC CGC CAC |
| NDUFB8     | **FW:** ACC CAA TCC AAC CGC CTT CA  
              **REV:** CTA GGA CCC CAG AGG AAC GC |
| PGC-1α     | **FW:** AGG AAA TCC GAG CTG AGC TGA ACA  
              **REV:** GCA AGA AGG CGA CAC ATC GAA CAA |
| Tubulin    | **FW:** CTC TCT GTC GAT TAC GGC AAG  
              **REV:** TGG TGA GGA TGG AGT TGT AGG |